Application of FBXO32 inhibitor in preparation of hepatocellular carcinoma treatment medicine
Through inhibitors and related diagnostic methods for FBXO32, the problem of unknown effect of FBXO32 in hepatocellular carcinoma was solved, effective treatment and diagnosis of HCC was achieved, and patient prognosis was improved.
Patent Information
- Application Number
- CN202411201767.0
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-08-29
- Publication Date
- 2024-11-22
AI Technical Summary
In the prior art, the specific role of FBXO32 in hepatocellular carcinoma (HCC) and its clinical value have not been fully discussed, and the prognosis of HCC is poor and there is a lack of effective treatment methods.
Develop inhibitors against FBXO32 for the preparation of hepatocellular carcinoma therapeutic drugs, and prepare PI3K-AKT signaling pathway for diagnosis and treatment by reducing the expression or activity of FBXO32, combining DNA methylation detection methods and specific antibodies. Pharmaceutical composition.
By inhibiting FBXO32, slowing or blocking the progression of HCC, new therapeutic strategies are provided and the diagnostic and therapeutic effects of HCC are improved through biomarkers and signaling pathway regulation.
Smart Images

Figure CN118987226A_ABST
Abstract
Description
Technical Field
[0001] The present invention relates to, in particular to use of an FBXO32 inhibitor in preparing a drug for treating hepatocellular carcinoma. Background Art
[0002] Hepatocellular carcinoma (HCC) is one of the most common malignancies worldwide and the third leading cause of cancer-related death. Despite certain advances in diagnosis and treatment, the overall prognosis of HCC remains poor, mainly due to its complex pathological mechanisms and highly heterogeneous characteristics. In recent years, researchers have gradually come to realize that the ubiquitin-proteasome system (UPS) plays a key role in the occurrence and development of HCC. The UPS is the main pathway for intracellular protein degradation, maintaining the balance of intracellular proteins through ubiquitin-mediated degradation of substrates. This process is completed by the synergistic action of three types of enzymes: ubiquitin-activating enzymes (E1), ubiquitin-conjugating enzymes (E2), and ubiquitin ligases (E3). Among them, E3 ligases play a key role in determining the specificity and selectivity of ubiquitinated substrates. Their dysregulation is common in many cancers, affecting cancer progression, development, and drug response.
[0003] Changes in the expression or activity of E3 ligases play a crucial role in many cancers. By regulating the ubiquitination of different substrates, E3 ligases exhibit oncogenic or tumor suppressor properties. As an important component of E3 ligases, the F-box protein family participates in a variety of cancer-related signaling pathways by ubiquitination and degradation of targeted substrates. Its potential application in cancer diagnosis and treatment has received extensive attention in preclinical and clinical studies. It has been reported that FBXO32 plays a key role in tumor malignant progression. FBXO32 stimulates protein synthesis by ubiquitination of eEF1A1, driving the progression and metastasis of pancreatic cancer. In breast cancer, FBXO32 mediates the ubiquitination and nuclear translocation of CtBP1 and promotes epithelial-mesenchymal transition (EMT). In addition, FBXO32 promotes the migration and invasion of lung adenocarcinoma by degrading PTEN through ubiquitination. However, although studies have shown that F-box proteins have important functions in various cancer types, their specific role in hepatocellular carcinoma (HCC) and their clinical value still need to be further explored. Summary of the invention
[0004] The purpose of the present invention is to solve the shortcomings of the prior art and to propose the use of FBXO32 inhibitor in the preparation of drugs for treating hepatocellular carcinoma.
[0005] To achieve the above-mentioned purpose, the present invention adopts the following technical scheme: use of FBXO32 inhibitor in the preparation of a drug for treating hepatocellular carcinoma.
[0006] Preferably, the drug for treating hepatocellular carcinoma has at least one of the following functions: promoting the proliferation of HCC cells and being positively correlated with the PI3K-AKT pathway.
[0007] Furthermore, a pharmaceutical composition for treating hepatocellular carcinoma comprises an inhibitor against FBXO32, which is used to reduce the expression or activity of FBXO32 to slow down or prevent the progression of HCC.
[0008] Furthermore, a biomarker for diagnosing hepatocellular carcinoma is provided, wherein the biomarker is the expression level of FBXO32 protein or its activity in HCC cells.
[0009] Furthermore, a DNA methylation detection method is provided for predicting the risk of HCC occurrence, wherein the method detects the methylation status of the DNA promoter region.
[0010] Furthermore, a method for detecting the interaction between FBXO32 and PHLPP2 comprises using co-immunoprecipitation technology or immunofluorescence co-localization technology to confirm the binding of FBXO32 to PHLPP2 and its effect on the PI3K-AKT pathway.
[0011] Furthermore, a specific antibody against FBXO32 is used to detect and quantify the expression level of FBXO32 in HCC cells; so as to evaluate its role in the occurrence and development of HCC.
[0012] Furthermore, a therapeutic method for regulating the PI3K-AKT signaling pathway includes inhibitory intervention against FBXO32; so as to activate the PI3K-AKT pathway by reducing the expression or function of FBXO32, thereby playing a role in the treatment of HCC.
[0013] Compared with the prior art, the beneficial effects of the present invention are as follows: through the present invention, DNA promoter hypomethylation can be obtained, leading to increased expression of FBXO32 in HCC cells, and the upregulated FBXO32 directly interacts with PHLPP2 to promote the ubiquitin proteasome degradation of PHLPP2, thereby activating the PI3K-AKT pathway, and further promoting the progression of HCC. BRIEF DESCRIPTION OF THE DRAWINGS
[0014] Figure 1 This is an experimental diagram showing that FBXO32 is highly expressed in hepatocellular carcinoma (HCC) and is associated with poor prognosis; Figure 2 This is an experimental diagram of FBXO32 promoting the proliferation of hepatocellular carcinoma cells; Figure 3 This is an experimental diagram of FBXO32 regulating the malignant phenotype of HCC; Figure 4This is the experimental diagram of FBXO32 regulating AKT signaling pathway; Figure 5 This is an experimental diagram showing that FBXO32 promotes the ubiquitination and proteasomal degradation of PHLPP2; Figure 6 The function of FBXO32 depends on the experimental diagram of PHLPP2; Figure 7 Figure 3. Experimental study showing that upregulation of FBXO32 in HCC is attributed to DNA hypomethylation. DETAILED DESCRIPTION
[0015] In order to provide a further understanding of the purpose, structure, features, and functions of the present invention, the following detailed description is given in conjunction with the embodiments.
[0016] Please refer to Figures 1 to 7 The present invention provides the use of FBXO32 inhibitor in preparing a drug for treating hepatocellular carcinoma.
[0017] PCR experiment primer sequences involved in the embodiment: primer sequences of human FBXO32 used for RT-qPCR experiment (F: forward primer sequence; R: reverse primer sequence) FBXO32 F: TTGGCCCTGGGTACATCATTTAACC; FBXO32 R: GACTGGTTAGTGACAGCTAAGGGGC; Interference gene sequences involved in the embodiment (three sequences of human FBXO32 gene lentiviral knockdown sh1-3): sh1 CAACAAGGAGGTATACAAT sh2 GGAAGAAGATGTATTTCAAAC sh3CCAAGCAAAGAGCAGTATGGA The materials and methods involved in the present invention are as follows: Tissues and cell lines: The HCC cell lines and HEK293T cells used in this study were obtained from the cell type culture collection of the Shanghai Cell Bank, China; these cell lines were maintained in Dulbecco’s modified Eagle’s medium (DMEM) containing 10% fetal bovine serum (Gibco, NY, USA) and cultured under standard conditions at 37°C and 5% CO2.
[0018] RNA extraction and qRT-PCR: RNA was extracted from HCC tissues and cell lines using TRIzol reagent (Invitrogen, USA). The extracted RNA was then reverse transcribed to generate complementary DNA (cDNA) as a template for quantitative reverse transcription PCR (qRT-PCR) analysis; the expression level of the human β-actin gene was used as a reference to normalize the expression of FBXO32.
[0019] (3) Western blotting: Total proteins from HCC tissues, matched adjacent normal tissues, and cell lines were extracted on ice using RIPA buffer (Beyotime, Shanghai, China). Proteins were separated by 10% SDS-PAGE (Beyotime) and subsequently transferred to a PVDF membrane. The membrane was incubated with the corresponding primary antibody overnight at 4°C, then washed three times with PBS and incubated with HRP-conjugated secondary antibody for 2 h. The ECL signal on the PVDF membrane was detected using an ECL kit containing BeyoECL Plus A and B (Beyotime). β-Actin was used as a loading control.
[0020] (4) Immunohistochemistry: Paraffin-embedded tissues were dewaxed with xylene and rehydrated through a graded ethanol series. Antigen retrieval was performed in a microwave oven using citrate buffer (pH 6.0). Tissue sections were blocked with hydrogen peroxide and incubated with the indicated antibodies.
[0021] (5) Cell line transfection: Cells at 50% confluence were infected with concentrated virus in the presence of 5 μg / ml polybrene. Infected cells were selected with 2 μg / ml puromycin (Merck, Darmstadt, Germany). Plasmid transfection was performed using Lipofectamine 3000 (Invitrogen, Carlsbad, CA, USA) according to the manufacturer's instructions.
[0022] Cell proliferation assay: For CCK-8 assay, HCC cells were cultured in 96-well plates; a fixed amount of CCK-8 solution (MCE, Monmouth Junction, NJ, USA) was added to each well at the indicated time points and incubated at 37°C for 2 h. The absorbance at 450 nm was measured using a Multiskan GO microplate reader (Thermo Fisher, Waltham, MA, USA); For colony formation assay, HCC cells were seeded in 6-well plates and cultured in 2 mL of culture medium for 10 days. Proliferating colonies were fixed with alcohol and stained with crystal violet. Visible colonies were photographed and counted. For EdU assay, transfected HCC cells were seeded in 12-well plates and cultured overnight. Subsequently, 50 μM EdU (Beyotime, Shanghai, China) was added to each well and incubated at 37°C for 2 h. The cells were then fixed, permeabilized, and nuclei were stained with 400 μL Hoechst 33342. Five areas were randomly selected in each well to count the number of cells to determine the proportion of EdU-positive cells.
[0023] Wound healing assay: Transfected hepatocellular carcinoma cells were seeded in 6-well plates; when the cells grew to 80% density, an artificial wound was made on the cell layer using a 200 μL pipette tip; images of the wound area were taken at the same location at 0 h and 24 h (s1 and s2). Relative cell motility was calculated using the formula: [(s1−s2) / s1].
[0024] Transwell assay: 200 μL serum-free medium containing (1 × 104) cells was added to the upper chamber of the Transwell plate, while 800 μL serum-containing medium was added to the lower chamber. After 24 hours, the remaining cells in the upper chamber were gently washed with PBS, and the migrated cells were fixed with 4% paraformaldehyde (PFA) for 15 minutes. After fixation, they were stained with crystal violet (Beyotime) for 30 minutes. The stained cells were then photographed and counted using an inverted optical microscope. For the invasion assay, Matrigel was added to the plate surface to assess the invasive ability of the cells.
[0025] In vivo mouse model: To evaluate the effect of FBXO32 on the malignant phenotype of HCC cells in vivo, (1 × 106) transfected HCC cells were suspended in PBS and injected subcutaneously into 4-week-old male nude mice; mice with similar body weight were randomly divided into experimental and control groups. Tumor size was measured and recorded once a week; for lung metastasis experiments, HCC cells stably expressing luciferase-tagged sh-con, sh-FBXO32, Lv-con, or Lv-FBXO32 were used. To construct a metastatic tumor model, PBS containing (1 × 106) cells was injected into the tail vein of nude mice; bioluminescence imaging (BLI) was performed 4 weeks later to identify metastatic foci.
[0026] Immunoprecipitation (IP) experiments: cells are transfected with the desired plasmids and lysed using ice-cold IP buffer; cell lysates containing the target protein are incubated with the indicated antibody-coupled beads overnight at 4°C; after incubation, proteins bound to the beads are eluted and analyzed by western blot using appropriate primary and secondary antibodies.
[0027] Ubiquitination assay: cells were transfected with the desired plasmids and lysed using lysis buffer containing 10% SDS; the lysate was denatured by heating at 100°C for 10 min; subsequently, the supernatant was diluted 10-fold with lysis buffer; then, the indicated molecules were collected by IP as described previously.
[0028] Bisulfite sequencing PCR (BSP) analysis: The extracted genomic DNA was bisulfite treated using the Methylation-Gold kit according to the manufacturer's instructions; the MethPrimer online bioinformatics tool was used to identify potential CpG islands in FBXO32 and design specific primers for quantitative methylation analysis; then, the bisulfite-treated genomic DNA was amplified using BSP primers.
[0029] Quantitative and statistical analysis: All statistical analyses were performed using GraphPad Prism software and IBM SPSS statistical software; Student's t-test and one-way ANOVA were used, and Tukey's post hoc test was performed to determine the significance level. The results are expressed as the mean ± SD of at least three independent experiments. The significance level is expressed as follows: *p<0.05; **p<0.01; ***p<0.001; ns, not significant.
[0030] like Figure 1 As shown, FBXO32 is highly expressed in hepatocellular carcinoma (HCC) and correlated with poor prognosis.
[0031] Using RNA-Seq data from the TCGA database, we obtained the expression profiles of the FBXO32 gene in normal liver tissues and HCC tissues.
[0032] The results showed that FBXO32 was significantly overexpressed in liver cancer (Figures 1A and 1B); at the same time, the expression of FBXO32 gradually increased in the late stages of liver cancer progression (Figure 1C).
[0033] Figure 1 A shows the mRNA expression levels of FBXO32 in tumor tissues and normal tissues from the TCGA database; Figure 1 Panel B shows the mRNA expression levels of FBXO32 in liver cancer tissues and normal liver tissues from the TCGA database; Figure 1 C illustrates that in HCC patients, up-regulation of FBXO32 mRNA expression was significantly correlated with tumor grade and stage.
[0034] Further analysis revealed that high expression levels of FBXO32 were significantly associated with poor overall survival in patients with liver cancer ( Figure 1 D).
[0035] Figure 1D shows the overall survival of patients with different FBXO32 expression levels using Kaplan-Meier analysis.
[0036] These results suggested that FBXO32 might play an important role in HCC, so we focused on FBXO32 in our study.
[0037] To verify the results of bioinformatics analysis, 50 pairs of HCC samples and their corresponding adjacent non-tumor liver tissue samples were subjected to qRT-PCR analysis, and the results showed that the expression of FBXO32 mRNA in HCC tissues was significantly higher than that in adjacent tissues (Figure 1E).
[0038] The waterfall plot in Figure 1E shows the log-scale fold changes in FBXO32 mRNA expression in 50 pairs of HCC and adjacent non-tumor tissues.
[0039] Immunohistochemistry (IHC) staining results showed that the IHC staining score of FBXO32 in tumor tissues was significantly higher than that in matched adjacent normal tissues ( Figures 1F and 1G ).
[0040] Figures 1F and 1G illustrate representative images of FBXO32 expression and immunohistochemistry (IHC) analysis in paired HCC specimens, n = 50 per group, scale bar, 50 mm.
[0041] Six pairs of HCC specimens were randomly selected to detect the expression of FBXO32 protein in HCC tissues. The results showed that the expression of FBXO32 protein in HCC tissues was significantly increased ( Figure 1H ).
[0042] Figure 1H shows that FBXO32 protein expression was detected in 6 pairs of HCC tissues and matched adjacent normal tissues Furthermore, survival analysis showed that increased FBXO32 expression was associated with poor overall survival in HCC patients ( Figure 1 I).
[0043] Survival analysis in Figure 1I after HCC patients were divided into FBXO32 low expression and high expression groups using the Kaplan-Meier method, n = 25 per group; all data are expressed as mean ± SD, *p < 0.05; **p < 0.01; ***p < 0.001; ns, indicating not significant; mean ± SD is Figure 1 Data presentation method of all statistical graphs in the table, * indicates statistically significant difference, ns indicates no statistically significant difference.
[0044] like Figure 2 As shown, FBXO32 promoted HCC cell proliferation.
[0045] The expression levels of FBXO32 in a normal hepatocyte cell line (THLE-2) and multiple HCC cell lines (HLF, Huh7, Hep3B, MHCC97L, MHCC97H) were measured by RT-qPCR and Western blotting. It was found that the expression of FBXO32 in HCC cells, especially in MHCC97H cells, was higher than that in THLE-2 cells at both mRNA and protein levels ( Figure 2 A and 2B).
[0046] Figure 2 RT-qPCR and Western blotting were used to analyze the expression levels of FBXO32 mRNA and protein in normal liver cell lines (THLE-2) and hepatocellular carcinoma (HCC) cell lines (HLF, Huh7, Hep3B, MHCC97L, MHCC97H) in A and 2B.
[0047] To further explore the role of FBXO32 in HCC, MHCC97H cells were transfected with shRNA-mediated FBXO32 knockdown (sh1, sh2, and sh3), while FBXO32-low-expressing Huh7 cells were overexpressed with lentivirus (Lv-FBXO32). After verifying the transfection efficiency of each group, it was found that sh2 showed a significant inhibitory effect in MHCC97H cells, and FBXO32-overexpressing Huh7 cells were also successfully constructed and used for subsequent functional experiments ( Figure 2 C and 2D).
[0048] Cell counting kit-8 (CCK-8) assay results showed that FBXO32 knockdown inhibited the viability of MHCC97H cells, while FBXO32 overexpression significantly increased the viability of Huh7 cells ( Figure 2 E and 2F).
[0049] In addition, 5'-ethynyl-2'-deoxyuridine (EdU) detection confirmed that in Huh7 cells with FBXO32 overexpression, the number of EdU-positive cells increased significantly, while that in cells with FBXO32 knockdown decreased ( Figure 2 G-2J).
[0050] Plate clone formation assay further showed that low expression of FBXO32 significantly inhibited the proliferation of MHCC97H cells, while overexpression of FBXO32 enhanced the proliferation of Huh7 cells ( Figure 2 K and 2L).
[0051] Figure 2 K and 2L illustrate the clone formation images and statistical results of MHCC97H and Huh7 cells in the given groups. All data are expressed as mean ± SD, *p<0.05; **p<0.01; ***p<0.001; ns, indicating not significant; mean ± SD is Figure 1 Data presentation method of all statistical graphs in the table, * indicates statistically significant difference, ns indicates no statistically significant difference.
[0052] like Figure 3 As shown, FBXO32 regulates the malignant phenotype of HCC.
[0053] Scratch healing and Transwell experimental models were constructed to evaluate the effects of FBXO32 dysregulation on HCC cell migration and invasion. The results showed that knocking down FBXO32 significantly inhibited cell migration and invasion. In contrast to the effects of knocking down FBXO32, overexpression of FBXO32 significantly promoted the malignant phenotype of HCC cells ( Figure 3 A-3H).
[0054] Figure 3 A and Figure 3 B shows the percentage of wound width measured and analyzed at 0 h and 24 h after scratch formation in MHCC97H cells; scale bar, 200 μm; Figure 3 C and Figure 3 D shows the percentage of wound width measured and analyzed at 0 h and 24 h after scratch formation in Huh7 cells. Scale bar, 200 μm; Figure 3 E and Figure 3F highlights the Transwell assay of MHCC97H cells after FBXO32 knockdown; the number of migrating and invading cells in each field of view was counted and analyzed; scale bar, 50 μm; Figure 3 G and Figure 3 H is a Transwell assay of Huh7 cells after FBXO32 overexpression. The number of migrating and invading cells in each field of view was counted and analyzed; scale bar, 50 μm.
[0055] To investigate the effect of FBXO32 on tumor growth in vivo, a mouse subcutaneous transplant tumor model was established; MHCC97H cells with FBXO32 knockdown, Huh7 cells with FBXO32 overexpression, and corresponding control HCC cells were subcutaneously injected into nude mice; a reduction in tumor volume was observed in the FBXO32 knockdown group, while FBXO32 overexpression produced the opposite effect ( Figure 3 I-3L).
[0056] Figure 3 I and Figure 3 J is a representative image of xenograft tumors formed by subcutaneous injection of MHCC97H-transfected cells and statistical analysis of xenograft tumor volumes; Figure 3 K and Figure 3 L, representative images of xenograft tumors formed by subcutaneous injection of Huh7-transfected cells and statistical analysis of xenograft tumor volumes.
[0057] In addition, to further investigate the effect of FBXO32 on HCC metastasis, we injected HCC cells carrying luciferase intravenously into nude mice and collected lung tissues 3 weeks later. Compared with the control group, the fluorescence intensity of the FBXO32 knockdown group was reduced. In contrast, FBXO32 overexpression promoted cell proliferation ( Figure 3 M-3P).
[0058] Figure 3 M and Figure 3 N is the in vivo fluorescence images captured after intravenous injection of MHCC97H-transfected cells and the statistical analysis of luciferase intensity.
[0059] Figure 3 O and Figure 3 P represents the in vivo fluorescence images captured after intravenous injection of Huh7 transfected cells and statistical analysis of luciferase intensity. All data are expressed as mean ± SD, *p<0.05; **p<0.01; ***p<0.001; ns, indicating not significant; mean ± SD is Figure 1 Data presentation method of all statistical graphs in the table, * indicates statistically significant difference, ns indicates no statistically significant difference.
[0060] In summary, our results confirmed that FBXO32 promotes the malignant phenotype of HCC both in vivo and in vitro.
[0061] like Figure 4 As shown, FBXO32 promotes HCC by enhancing AKT phosphorylation.
[0062] Preliminary experiments have elucidated the role of FBXO32 in promoting the proliferation, migration and invasion of HCC cells in vitro, and demonstrated that FBXO32 enhances the tumorigenicity and migration of HCC cells in vivo.
[0063] However, the specific mechanism by which FBXO32 exerts its function remains unclear. To address this issue, the protein interaction network of FBXO32 was analyzed using the STRING database ( Figure 4 A), and KEGG pathway enrichment analysis was performed. The study found that FBXO32-related proteins are involved in multiple cancer-related pathways, especially the PI3K-AKT signaling pathway ( Figure 4 B).
[0064] To verify whether FBXO32 activated this pathway in HCC, the expression of related pathway proteins was measured by Western blotting. The results showed that the level of phosphorylated AKT (p-AKT) was reduced in MHCC97H cells with FBXO32 knockdown, while the level of p-AKT was increased in Huh7 cells with FBXO32 overexpression ( Figure 4 C). In vivo fluorescence images obtained to investigate AKT activity. Statistical analysis of luciferase intensity.
[0065] Figure 4 In C, levels of total and phosphorylated AKT in MHCC97H and Huh7 cells, with β-actin as a loading control.
[0066] To investigate whether AKT activity mediates the role of FBXO32 in HCC progression, Huh7 cells were treated with p-AKT inhibitor MK-2206 ( Figure 4 D); Figure 4 D: Western blotting analysis of Lv-con and Lv-FBXO32 cells treated with MK-2206 (1 µM) or DMSO.
[0067] CCK-8, EdU and clone formation assays showed that MK-2206 blocked the promoting effect of FBXO32 overexpression on Huh7 cell viability and proliferation ( Figure 4 E-4I); Figure 4E is CCK-8 analysis of Lv-con and Lv-FBXO32 cells treated with MK-2206 and DMSO; Figure 4 F and Figure 4 In G, EdU analysis of Lv-con and Lv-FBXO32 cells treated with MK-2206 and DMSO, scale bar: 50 μm.
[0068] Figure 4 H and Figure 4 In I, representative images and statistical analysis of the clonogenic assay, Lv-con and Lv-FBXO32 cells were treated with MK-2206 or DMSO.
[0069] In addition, MK-2206 also inhibited the migration and invasion enhanced by FBXO32 overexpression ( Figure 4 J-4K); Figure 4 J and Figure 4 In K, Transwell assay images of migration and invasion and statistical analysis results, Lv-con and Lv-FBXO32 cells were treated with MK-2206 and DMSO; scale bar: 50 μm.
[0070] All data are expressed as mean ± SD, *p<0.05; **p<0.01; ***p<0.001; ns, indicating not significant.
[0071] Taken together, these results suggest that FBXO32 plays a role in HCC progression by activating the AKT signaling pathway.
[0072] like Figure 5 As shown, FBXO32 promotes the ubiquitination and proteasomal degradation of PHLPP2.
[0073] To further elucidate the molecular mechanism by which FBXO32 regulates the AKT signaling pathway, we hypothesized that the E3 ligase FBXO32 increases the phosphorylation of AKT by reducing the levels and / or activities of AKT phosphatases such as PHLPP1 and PHLPP2, PTEN, PP1, and PP2A. Figure 5 A).
[0074] Figure 5 A shows the mechanism by which FBXO32 induces HCC progression via the PI3K-AKT pathway.
[0075] By examining the changes in the levels of these phosphatases, we found that PHLPP2 protein levels were specifically reduced in FBXO32-overexpressing cells, while other phosphatases did not change significantly ( Figure 5 B).
[0076] Figure 5 B, Western blot analysis of FBXO32-overexpressing cells using the indicated antibodies.
[0077] To verify the interaction between proteins, we used anti-Flag antibody to perform immunoprecipitation (IP) experiments in Flag-FBXO32 overexpressing cells, and the results confirmed that PHLPP2 has a strong binding ability with FBXO32 ( Figure 5 C).
[0078] Figure 5 C: Immunoprecipitation (IP) experiment to verify the candidate binding proteins of FBXO32.
[0079] This result was further confirmed by endogenous IP experiments and molecular docking analysis ( Figure 5 D and 5E). Figure 5 D is an endogenous immunoprecipitation (IP) experiment verifying the binding of FBXO32 to PHLPP2 in HCC cells; Figure 5 In E, HDOCK SERVER was used to predict the potential binding conformation of FBXO32 and PHLPP2, and the resulting docking score was -258.60.
[0080] Western blot analysis further confirmed that FBXO32 negatively regulated PHLPP2 protein expression in HCC cells ( Figure 5 F). Figure 5 F is the expression level of PHLPP2 after FBXO32 knockdown or overexpression These results suggest that FBXO32 functions by interacting with the AKT phosphatase PHLPP2 and reducing its protein levels.
[0081] To explore how FBXO32 regulates the expression of PHLPP2, cells were treated with cycloheximide (CHX) to block protein synthesis, and the protein level of PHLPP2 was detected. The results showed that FBXO32 promoted the degradation of PHLPP2 protein ( Figure 5 G ), Western blot analysis of cells transfected with Lv-FBXO32 and treated with 50 µg / ml CHX for the indicated times.
[0082] Furthermore, treatment of FBXO32-overexpressing and control cells with the lysosomal inhibitor chloroquine (CQ) or the proteasome inhibitor MG132 showed that MG132, but not CQ, prevented the decrease in PHLPP2 protein levels caused by FBXO32 overexpression ( Figure 5H), PHLPP2 expression in FBXO32-overexpressing HEK293T cells after treatment with the protein synthesis inhibitor CHX (50 µg / ml) combined with MG132 (10 µM) or CQ (20 µM). DMSO treatment served as a control.
[0083] It was demonstrated that PHLPP2 is degraded through the ubiquitin-proteasome pathway.
[0084] Then, FBXO32 knockdown reduced the ubiquitination of PHLPP2, while FBXO32 overexpression showed the opposite effect ( Figure 5 I and 5J). Figure 5 I: ubiquitination of PHLPP2 after FBXO32 knockdown or overexpression in HCC cells; In addition, it was demonstrated that FBXO32 promotes K48-linked ubiquitination of PHLPP2 ( Figure 5 K), Representative Western blot analysis showing K48-linked ubiquitination of PHLPP2 in HEK293T cells.
[0085] We further predicted the ubiquitination sites of PHLPP2 and confirmed that FBXO32 mediates K48-linked polyubiquitination of PHLPP2 via lysine residues K592 and K942 ( Figure 5 L and 5M); Figure 5 L used GPS-Uber tool to predict the ubiquitination modified lysine sites of PHLPP2; Figure 5 M is a representative Western blot analysis showing K48-linked ubiquitination of PHLPP2 at K592 and K942 in HEK293T cells.
[0086] like Figure 6 As shown, FBXO32 promotes HCC progression through the PHLPP2-AKT signaling pathway.
[0087] To evaluate whether the effect of FBXO32 on HCC progression is dependent on the PHLPP2-AKT pathway, Lv-con and Lv-FBXO32 Huh7 cells were transfected with lentiviruses expressing PHLPP2 overexpression (PHLPP2-OE) or control (Vector), respectively.
[0088] Western blot analysis confirmed that PHLPP2-OE attenuated FBXO32-induced AKT activation ( Figure 6 A), Western blot analysis showed the protein levels of FBXO32, PHLPP2, total AKT, and phosphorylated AKT in each group.
[0089] CCK-8, EdU and colony formation assays showed that the increase in cell viability and proliferation efficiency caused by upregulation of FBXO32 was blocked by PHLPP2-OE ( Figure 6 B-6F); Figure 6 B is the CCK-8 test results of HCC cells in each group; Figure 6 C and Figure 6 D is the EdU detection results and proliferation efficiency of HCC cells in each group, scale bar, 50 μm; Figure 6 E and Figure 6 F is the colony formation experiment results of HCC cells in each group; Regarding cell migration and invasion, Transwell assays showed that the promotion of these processes by upregulation of FBXO32 was also blocked by PHLPP2-OE ( Figure 6 G and 6H); Figure 6 G and Figure 6 H is the representative Transwell assay results and statistical analysis of HCC cell migration and invasion in each group, scale bar, 50 μm.
[0090] All data are expressed as mean ± SD, *p<0.05; **p<0.01; ***p<0.001; ns, not significant; mean ± SD Figure 1 Data presentation method of all statistical graphs in the table, * indicates statistically significant difference, ns indicates no statistically significant difference.
[0091] Collectively, these data suggest that the regulatory effect of FBXO32 on HCC progression is dependent on the PHLPP2-AKT signaling pathway.
[0092] like Figure 7 As shown, upregulation of FBXO32 was attributed to DNA promoter hypomethylation.
[0093] To further explore the mechanism of FBXO32 upregulation in hepatocellular carcinoma (HCC), bioinformatics analysis showed that FBXO32 mRNA expression was negatively correlated with DNA methylation level ( Figure 7 A), The relationship between DNA methylation level and FBXO32 mRNA expression in HCC was analyzed using cBioPortal database.
[0094] By exposing MHCC97H cells with relatively high FBXO32 expression and Huh7 cells with relatively low FBXO32 expression to 5-Aza-dC (a widely used DNA methyltransferase inhibitor), both FBXO32 mRNA and protein expression in cells exposed to 5-Aza-dC were significantly upregulated compared with untreated cells, indicating that FBXO32 expression is negatively correlated with DNA methylation levels ( Figure 7 B and 7C).
[0095] Figure 7 B, evaluation of FBXO32 mRNA expression levels in HCC cells after 5-Aza-dC treatment; Figure 7 C: Evaluation of the expression level of FBXO32 protein in HCC cells after 5-Aza-dC treatment.
[0096] In addition, bioinformatics analysis showed that the promoter region of FBXO32 contained a typical CpG island ( Figure 7 D) The online tool MethPrimer was used to screen the potential methylated CpG islands in the promoter sequence of FBXO32.
[0097] Bisulfite sequencing PCR (BSP) results showed that the FBXO32 DNA promoter sequence in tumors was hypomethylated compared with adjacent normal tissues ( Figure 7 E and 7F).
[0098] Figure 7 E and 7F show the DNA methylation status of FBXO32 CpG islands in six randomly selected HCC tissues and their matched adjacent normal tissues determined by BSP assay. Unmethylated CpG sites are indicated by open circles, and methylated CpG sites are indicated by solid circles.
[0099] In summary, the results of this study suggest that the upregulation of FBXO32 in HCC may be attributed to DNA promoter hypomethylation; upregulated FBXO32 promotes K48-linked polyubiquitination of PHLPP2 via lysine residues K592 and K942, leading to PHLPP2 degradation and activation of the PI3K-AKT signaling pathway, thereby promoting the malignant progression of HCC ( Figure 7 G).
[0100] Figure 7 G Schematic diagram illustrating the mechanism of FBXO32 in HCC. All data are expressed as mean ± SD, *p < 0.05; **p < 0.01; ***p < 0.001; ns, not significant; mean ± SD Figure 1 Data presentation method of all statistical graphs in the table, * indicates statistically significant difference, ns indicates no statistically significant difference.
[0101] The present study showed that the upregulation of E3 ligase F-box protein family FBXO32 in HCC may be caused by DNA promoter hypomethylation. Increased FBXO32 levels promoted K48 chain polyubiquitination of PHLPP2 at lysine residues K592 and K942, leading to the degradation of PHLPP2, activation of PI3K-AKT signaling pathway and malignant progression of HCC. Ubiquitination regulation is crucial in tumorigenesis, and FBXO32 plays an important role in various tumors through carcinogenic and tumor suppressor functions.
[0102] Furthermore, the present study also revealed that FBXO32 is a new driver of HCC progression. During the experiment, the present invention observed that FBXO32 expression was upregulated in human HCC specimens, and higher expression levels predicted poorer patient prognosis. In addition, increased FBXO32 expression levels in HCC patients were significantly associated with advanced disease. Therefore, targeting FBXO32 provides a promising therapeutic strategy for inhibiting tumor progression in HCC patients.
[0103] In summary, in this study, it was demonstrated that FBXO32 interacts with PHLPP2 and promotes its ubiquitination in HCC cells. These findings reveal a new function of PHLPP2 in HCC, indicating that PHLPP2 levels are reduced in HCC tissues with FBXO32 amplification, leading to increased p-AKT levels and promoting tumor malignancy.
[0104] The present study showed that FBXO32 is an independent prognostic biomarker in HCC and plays an important role in promoting the malignant progression of HCC. In addition, this study provides detailed mechanistic insights into HCC progression and provides a promising potential therapeutic target for the precision treatment of HCC.
[0105] The present invention has been described by the above-mentioned relevant embodiments, however, the above-mentioned embodiments are only examples for implementing the present invention. It must be pointed out that the disclosed embodiments do not limit the scope of the present invention. On the contrary, changes and modifications made without departing from the spirit and scope of the present invention are all within the scope of patent protection of the present invention.
Claims
1. Use of FBXO32 inhibitors in the preparation of drugs for the treatment of hepatocellular carcinoma.
2. The use of FBXO32 in a drug for treating hepatocellular carcinoma by degrading PHLPP2 as claimed in claim 1, characterized in that: The hepatocellular carcinoma therapeutic drug has at least one of the following functions: promoting the proliferation of HCC cells and being positively correlated with the PI3K-AKT pathway.
3. A pharmaceutical composition for treating hepatocellular carcinoma, characterized in that: The pharmaceutical composition comprises an inhibitor targeting FBXO32, and is used for reducing the expression or activity of FBXO32, so as to slow down or prevent the progression of HCC.
4. A biomarker for diagnosing hepatocellular carcinoma, characterized in that: The biomarker is the expression level of FBXO32 protein or its activity in HCC cells.
5. A method for detecting DNA methylation, characterized in that: Used to predict the risk of HCC, wherein the method detects the methylation status of the DNA promoter region.
6. A method for detecting the interaction between FBXO32 and PHLPP2, characterized in that: This includes using co-immunoprecipitation or immunofluorescence co-localization techniques to confirm the binding of FBXO32 to PHLPP2 and its effect on the PI3K-AKT pathway.
7. A specific antibody against FBXO32, characterized in that: Used to detect and quantify the expression level of FBXO32 in HCC cells.
8. A therapeutic method for regulating the PI3K-AKT signaling pathway, characterized in that: Including inhibitory interventions targeting FBXO32.
